SCHEMBL110284

SCHEMBL110284

CCCC(=O)O[C@]1(C(=O)CS)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](OC(=O)CC)C[C@@]21C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 7/20 0.69
PGR P06401 4/20 0.69
NR3C1 P04150 4/20 0.69
HIF1A Q16665 5/20 0.63
KMT2A Q03164 2/20 0.63
AR P10275 3/20 0.60
CHRM1 P11229 1/20 0.60
CYP3A4 P08684 4/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NR1I2 O75469 2/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 1/20 0.53
MEN1 O00255 1/20 0.53
MLNR O43193 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTT P42858 1/20 0.53
SLC6A3 Q01959 1/20 0.53
PDE4D Q08499 1/20 0.53
PDE3A Q14432 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122186 0.93 NR3C2 (0.79) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL1807730 0.92 PGR (0.68) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL1807731 0.90 PGR (0.70) NR3C2PGRNR3C1HIF1AKMT2A
Butixocort SCHEMBL23803956 0.89 NR3C2 (0.86) NR3C2PGRNR3C1HIF1AKMT2A
Butixocort SCHEMBL109157 0.89 NR3C2 (0.86) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL23803941 0.85 HIF1A (0.60) NR3C2PGRNR3C1HIF1AKMT2A
Resocortol Butyrate SCHEMBL2110603 0.84 NR3C2 (0.89) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL23456329 0.83 NR3C2 (0.70) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL10535271 0.82 NR3C2 (0.80) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11581184 0.82 NR3C2 (0.89) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2776 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130899-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2026-05-14 US claimed
EP-4126138-B1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS INVOX BELGIUM NV (BE) 2024-10-16 EP claimed
US-20240216353-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-07-04 US claimed
EP-4126138-A1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS Softhale NV (BE) 2023-02-08 EP claimed
US-20220096498-A1 INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION FORDOZ PHARMA CORP. (US) 2022-03-31 US claimed
US-11247969-B2 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-02-15 US claimed
US-20210315873-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-10-14 US claimed
WO-2021198154-A1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS SOFTHALE NV (BE) 2021-10-07 WO claimed
US-10919934-B2 Compositions and methods for managing respiratory conditions EMORY UNIVERSITY (US) 2021-02-16 US claimed
WO-2020227353-A1 INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION FORDOZ PHARMA CORP. (US) 2020-11-12 WO claimed
EP-1341542-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2003-09-10 EP claimed
US-20020164290-A1 Biocompatible compounds for sustained release pharmaceutical drug delivery systems 3M INNOVATIVE PROPERTIES COMPANY 2002-11-07 US claimed
US-6416742-B1 DISSOLVED POLYLACTONE, POLYTHIOESTER, OR POLYLACTAM AND FLUOROCARBON PROPELLANT; BIODEGRADABLE POLYMER STABILIZES AND SOLUBILIZES THE DRUG; SUSTAINED RELEASE 3M INNOVATIVE PROPERTIES COMPANY 2002-07-09 US claimed
WO-2002045703-A2 MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENTOF AIRWAY DISEASES NOVARTIS AG (CH) 2002-06-13 WO claimed
US-6126919-A METERED DOSE INHALER FOR SUSTAINED RELEASE 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-10-03 US claimed
EP-1014944-A2 BIOCOMPATIBLE COMPOUNDS FOR PHARMACEUTICAL DRUG DELIVERY SYSTEMS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2000-07-05 EP claimed
WO-1998034596-A2 BIOCOMPATIBLE COMPOUNDS FOR PHARMACEUTICAL DRUG DELIVERY SYSTEMS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-08-13 WO claimed
EP-0817611-A1 BUTIXOCORT AEROSOL FORMULATIONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-01-14 EP claimed
US-5653961-A SOLUTION COMPRISING NON-OZONE DEPLETING 1,1,1,2-TETRAFLUOROETHANE AND/OR 1,1,1,2,3,3,3-HEPTAFLUOROPROPANE; BRONCHIAL ASTHMA; STORAGE STABILITY MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-08-05 US claimed
WO-1996029985-A1 BUTIXOCORT AEROSOL FORMULATIONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-10-03 WO claimed